“Prospective Real-Life Multicenter Study of Tildrakizumab 200 Mg for Moderate-to-Severe Psoriasis: Who Is the Ideal Patient?”. Dermatology Practical & Conceptual, vol. 14, no. 4, Oct. 2024, p. e2024284, https://doi.org/10.5826/dpc.1404a284.